DAWNZERA Solution for injection Ref.[116238] Active ingredients: Donidalorsen

Source: European Medicines Agency (EU)  Revision Year: 2026  Publisher: Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT Amsterdam, Netherlands

Product name and form

Dawnzera 80 mg solution for injection in pre-filled pen.

Pharmaceutical Form

Solution for injection (injection).

Clear, colourless to yellow solution with a pH of approximately 7.4 and osmolality of approximately 290 mOsm/kg.

Qualitative and quantitative composition

Each pre-filled pen contains 80 mg donidalorsen (as donidalorsen sodium) in 0.8 mL of solution.

For the full list of excipients, see section 6.1.

Active Ingredient

Donidalorsen is a 2'-O-methoxyethyl–modified antisense oligonucleotide (ASO) conjugated to a triantennary N-acetylgalactosamine (GalNAc3) moiety that causes ribonuclease H1 (RNase H1) mediated degradation of prekallikrein (PKK) mRNA through selective binding to PKK mRNA, which results in reduced production of PKK protein. PKK is a pro-enzyme for plasma kallikrein, which results in the release of bradykinin, a potent vasodilator causing inflammation and swelling in hereditary angioedema (HAE).

List of Excipients

Sodium dihydrogen phosphate (E339)
Disodium hydrogen phosphate (E339)
Sodium chloride
Water for injections
Hydrochloric acid (E507) (for pH adjustment)
Sodium hydroxide (E524) (for pH adjustment)

Pack sizes and marketing

0.8 mL sterile solution in a single-use Type I glass syringe with a stainless steel staked needle, rigid needle shield, and siliconised chlorobutyl elastomer plunger stopper. The filled primary container and a pen are assembled to a pre-filled pen, which is labelled and packaged in an opaque carton with a partition to secure the pre-filled pen and protect from light.

Pack size of one pre-filled pen.

Pack size of three pre-filled pens.

Not all pack sizes may be marketed.

Marketing authorization holder

Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT Amsterdam, Netherlands

Marketing authorization dates and numbers

EU/1/25/2001/001
EU/1/25/2001/002

Drugs

Drug Countries
DAWNZERA Austria, Estonia, Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.